Bevacizumab, a VEGFI, is associated with cardiovascular toxicities such as hypertension and thrombosis due to vascular endothelial damage caused by VEGF inhibition (Ferrara, 2004), while ICIs cause myocarditis and other conditions through activation of various immune responses, including T cells (Moslehi et al., 2021). This evidence concerns the gene VEGFA and Hypertension.